Success of the capital increase
Success of the capital increaseFINANCING ISSUE
The capital increase announced at the end of April was a success, the group raising its c.€8m target to finance the group until the launch of Zepizure in the US. The stake of its reference shareholder (Gemmes Venture) was unchanged at 24.28% after it subscribed c. 1.06m shares. This shareholder had committed to subscribing for up to 75% of the capital increase.
FACT
Crossject announced the positive outcome of its planned capital increase.
ANALYSIS
The successful closing of its rights offering with maintained preferential subscription rights was announced by the group, for a gross amount of c.€8m (also see our Latest dated 2 May, 2024). The proceeds will be used to finance the market launch of Zepizure (Midazolam) in the US (about 50% of proceeds) as well as to build its US operations with a view to commercializing this NTE directly and in its manufacturing activities (20%) as well as develop new NTEs (Hydrocortisone and Adrenaline), (with the EUA (Emergency Use Authorization) for Zepizure expected in Q1 25 and full authorization in H12 5.
A total of c.4.3m shares were subscribed at a price of €1.848 per share. Gemmes Venture, the group’s reference shareholder, subscribed for c. 1.058m new shares on a non-reducible basis, and holds an unchanged 24.48% stake in Crossject.
IMPACT
We will integrate the new shares and the implied dilution, together with the cash inflow aimed at financing the short-term needs of the company. The management has reiterated that this round of financing will enable them “to reach the regulatory filing milestones for Zepizure in 2025”, which is good news as we previously wrote (5 May, 2024) but obviously does not completely exclude new financings before the product reaches the market. The management has also indicated that this capital increase will “support its ability to source additional non-dilutive financing”, which we can only hope.
Note that we will also revise our assumptions for the launch of the group’s NTEs in the next few days.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.